DrugDashboards

Ofloxacin

Ofloxacin Otic · OFLOXACIN 3 mg/mL · Solution · Auricular (Otic) · Amneal Pharmaceuticals NY LLC

NDC 69238-1615-03 · 1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price is down 22% over the past year, to $1.11 per mL. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$1.11per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D point of sale (median)$2.36per unitnegotiated price across 5,496 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$2.36per unit
middle half $1.91$4.20 · 5,496 plans · Apr 1, 2026
Est. net of rebates
≈ $2.36
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 5 quarters since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Jun 2020Sep 2026$1.11
76 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$15.00
Reported to Texas DSHS · 2026 annual filing · Amneal Pharmaceuticals LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$2.2M
117,938 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

8Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 21% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for ofloxacin (other) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA211525
TE code
AT
Approval date
Aug 30, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedApr 13, 2022
    Mckesson Medical-Surgical Inc. Corporate OfficecGMP deviations: Temperature abuse

Manufacturers of Ofloxacin Otic (Solution)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals NY LLCOFLOXACIN 3 mg/mLJul 15, 2026Sep 3, 2026
Asclemed USA, Inc.OFLOXACIN 3 mg/mLJul 15, 2026Sep 3, 2026
Lifestar Pharma LLCOFLOXACIN 3 mg/mLJul 15, 2026Sep 3, 2026
Remedyrepack Inc.OFLOXACIN 3 mg/mLJul 15, 2026Sep 3, 2026
NorthStar RxLLCOFLOXACIN 3 mg/mLJul 15, 2026Sep 2, 2026
NuCare Pharmaceuticals,Inc.OFLOXACIN 3 mg/mLJul 15, 2026Sep 2, 2026
Proficient Rx LPOFLOXACIN 3 mg/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsOFLOXACIN 3 mg/mLJul 15, 2026Aug 28, 2026
Sportpharm LLCOFLOXACIN 3 mg/mLJul 15, 2026Aug 28, 2026
Preferred Pharmaceuticals Inc.OFLOXACIN 3 mg/mLJul 15, 2026Aug 5, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ofloxacin — NDC 69238-1615-03," retrieved September 3, 2026, https://drugdashboards.com/drug/69238161503.

Free to cite with attribution — see how the data is put together.